

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,849-A)

PATENT

RECEIVED

MAR 29 2000

TECH CENTER 1600/293

In application of:

Odile Leroy

Serial No. 09/423,698

Filed: November 12, 1999

For: Multivalent Vaccine Composition with Mixed
Carrier

Group Art Unit:

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449. Because some of the references cited herein are not in the English language, a concise explanation of these references pursuant to Rule 1.98 (a)(3) is provided.


In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington D.C. 20231, on January 11, 2000.

Date: January 11, 2000


Michael S. Greenfield

RECEIVED

MAR 29 2000


TECH CENTER 1600/2900

1. International Publication No. WO 88 00056, published January 14, 1988
2. European Patent No. 0 497 525, published August 5, 1992
3. C. Chu et al.: "Further Studies on the Immunogenicity of Haemophilus Influenzae Type B and Pneumococcal Type 6A Polysaccharide-Protein Conjugates", *Infection and Immunity*, vol. 40, no. 1, April 1983, pages 245-256
4. D.P. Greenberg et al.: "Factors Influencing the Immunogenicity of a Pneumococcal Conjugate Vaccine in Infants", *Pediatric Research*, vol. 41, 2-6 May 1997, page 121A
5. G.R. Siber: "Pneumococcal Disease: Prospects for a New Generation of Vaccines", *Science*, vol. 265, September 2 1994, pages 1385-1387
6. C.C.A.M. Peeters et al.: "Effect of Carrier Priming on Immunogenicity of Saccharide-Protein Conjugate Vaccines", *Infection and Immunity*, vol. 50, no. 10, October 1991, pages 3504-3510
7. R. Dagan et al.: "Reduced Response to Multiple Vaccines Sharing Common Protein Epitopes That Are Administered Simultaneously to Infants", *Infection and Immunity*, vol. 66, no. 5, May 1998, pages 2093-2098

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Date: January 11, 2000

By:


Michael S. Greenfield
Reg. No. 37,142